Department Of Human Genetics And Molecular Medicine

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/103

Browse

Search Results

Now showing 1 - 6 of 6
  • Item
    Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal models
    (Springer Science and Business Media Deutschland GmbH, 2023-11-03T00:00:00) Haque, Shafiul; Hussain, Arif; Joshi, Hemant; Sharma, Ujjawal; Sharma, Bunty; Aggarwal, Diwakar; Rani, Isha; Ramniwas, Seema; Gupta, Madhu; Tuli, Hardeep Singh
    Background: Melittin is a water-soluble cationic peptide derived from bee venom that has been thoroughly studied for the cure of different cancers. However, the unwanted interactions of melittin produce hemolytic and cytotoxic effects that hinder their therapeutic applications. To overcome the shortcomings, numerous research groups have adopted different approaches, including conjugation with tumor-targeting proteins, gene therapy, and encapsulation in nanoparticles, to reduce the non-specific cytotoxic effects and potentiate their anti-cancerous activity. Purpose: This article aims to provide mechanistic insights into the chemopreventive activity of melittin and its nanoversion in combination with standard anti-cancer drugs for the treatment of cancer. Methods: We looked over the pertinent research on melittin's chemopreventive properties in online databases such as PubMed and Scopus. Conclusion: In the present article, the anti-cancerous effects of melittin on different cancers have been discussed very nicely, as have their possible mechanisms of action to act against different tumors. Besides, it interacts with different signal molecules that regulate the diverse pathways of cancerous cells, such as cell cycle arrest, apoptosis, metastasis, angiogenesis, and inflammation. We also discussed the recent progress in the synergistic combination of melittin with standard anti-cancer drugs and a nano-formulated version of melittin for targeted delivery to improve its anticancer potential. Graphical abstract: [Figure not available: see fulltext.] � 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
  • Item
    Potential use of cidofovir, brincidofovir, and tecovirimat drugs in fighting monkeypox infection: recent trends and advancements
    (Springer Science and Business Media Deutschland GmbH, 2023-10-14T00:00:00) Rani, Isha; Joshi, Hemant; Sharma, Ujjawal; Kaur, Jagjit; Sood, Shivani; Ramniwas, Seema; Chauhan, Abhishek; Abdulabbas, Hadi Sajid; Tuli, Hardeep Singh
    Recent years have witnessed the rise of more recent pandemic outbreaks including COVID-19 and monkeypox. A multinational monkeypox outbreak creates a complex situation that necessitates countermeasures to the existing quo. The first incidence of monkeypox was documented in the 1970s, and further outbreaks led to a public health emergency of international concern. Yet as of right now, neither vaccines nor medicines are certain to treat monkeypox. Even the inability of conducting human clinical trials has prevented thousands of patients from receiving effective disease management. The current state of the disease�s understanding, the treatment options available, financial resources, and lastly international policies to control an epidemic state are the major obstacles to controlling epidemics. The current review focuses on the epidemiology of monkeypox, scientific ideas, and available treatments, including potential monkeypox therapeutic methods. As a result, a thorough understanding of monkeypox literature will facilitate in the development of new therapeutic medications for the prevention and treatment of monkeypox. � 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
  • Item
    Artificial Intelligence Bringing Newer Paradigms in the Diagnosis, Treatment, and Management of Psoriasis
    (Springer, 2023-10-04T00:00:00) Sharma, Ravi Kant; Sharma, Manu Rashmi; Mahendra, Aneet; Sharma, Ujjawal; Singh, Simranjit; Ramniwas, Seema; Sharma, Anil Kumar
    Purpose of Review: As we know, psoriasis is the most prevalent chronic inflammatory skin condition due to aberrant immune response which is characterized by clearly demarcated red or pink thick raised skin plaques sometimes covered with dry thin silvery white scales, formed due to the cytokine-driven hyperproliferation of epidermal keratinocytes. The abnormal functioning of immune-inflammatory pathways can cause various systemic conditions including cardiovascular diseases, chronic renal disease, and metabolic syndrome. Recent Findings: In comparison to other dermatological conditions, psoriasis has greater impact on the mental health of patients leading to increased risk of psychiatric comorbidities such as depression and anxiety.�The Articial intellingence could automate the analysis and provide contextual relevance, enhance clinical reliability,�assist the clinicians in communicating objectively, minimize human fatigue related errors, decrease mortality rates,�save medical expenditures and help in easy and early diagnosis of diseases including psoriasis. Summary: Therefore, development of better approaches for the diagnosis of psoriasis and determination of its classification type and severity are necessary for disease control and management and are the need of the hour. The artificial intelligence (AI) applications in medicine and healthcare are recently emerging due to advanced computing technologies and availability of abundant data on a variety of diseases including psoriasis. Hence, AI will certainly be a boon for the early detection and management of psoriasis patients necessitating further research in this area. � 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
  • Item
    Temozolomide and flavonoids against glioma: from absorption and metabolism to exosomal delivery
    (Springer Science and Business Media Deutschland GmbH, 2023-08-11T00:00:00) Verma, Priyanka; Joshi, Hemant; Singh, Tejveer; Sharma, Bunty; Sharma, Ujjawal; Ramniwas, Seema; Rana, Rashmi; Gupta, Madhu; Kaur, Ginpreet; Tuli, Hardeep Singh
    Patients with glioblastoma multiforme and anaplastic astrocytoma are treated with temozolomide. Although it has been demonstrated that temozolomide increases GBM patient survival, it has also been connected to negative immune-related adverse effects. Numerous research investigations have shown that flavonoids have strong antioxidant and chemo-preventive effects. Consequently, it might lessen chemotherapeutic medicines� side effects while also increasing therapeutic effectiveness. The need for creating innovative, secure, and efficient drug carriers for cancer therapy has increased over time. Recent research indicates that exosomes have enormous potential to serve as carriers and cutting-edge drug delivery systems to the target cell. In recent years, researchers have been paying considerable attention to exosomes because of their favorable biodistribution, biocompatibility, and low immunogenicity. In the present review, the mechanistic information of the anti-glioblastoma effects of temozolomide and flavonoids coupled with their exosomal delivery to the targeted cell has been discussed. In addition, we discuss the safety aspects of temozolomide and flavonoids against glioma. The in-depth information of temozolomide and flavonoids action via exosomal delivery can unravel novel strategies to target Glioma. � 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
  • Item
    Apoptotic and antimetastatic effect of cucurbitacins in cancer: recent trends and advancement
    (Springer Science and Business Media Deutschland GmbH, 2023-04-03T00:00:00) Kumar, Ajay; Sharma, Bunty; Sharma, Ujjawal; Parashar, Gaurav; Parashar, Nidarshana Chaturvedi; Rani, Isha; Ramniwas, Seema; Kaur, Satwinderjeet; Haque, Shafiul; Tuli, Hardeep Singh
    The Cucurbitaceae family produces a class of secondary metabolites known as cucurbitacins. The eight cucurbitacin subunits are cucurbitacin B, D, E, I, IIa, L glucoside, Q, and R with the most significant anticancer activity. They are reported to inhibit cell proliferation, invasion, and migration; induce apoptosis; and encourage cell cycle arrest, as some of their modes of action. The JAK-STAT3, Wnt, PI3K/Akt, and MAPK signaling pathways, which are essential for the survival and apoptosis of cancer cells, have also been shown to be suppressed by cucurbitacins. The goal of the current study is to summarize potential molecular targets that cucurbitacins could inhibit in order to suppress various malignant processes. The review is noteworthy since it presents all putative molecular targets for cucurbitacins in cancer on a single podium. � 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
  • Item
    Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
    (MDPI, 2022-11-08T00:00:00) Singh Tuli, Hardeep; Kumar, Ajay; Ramniwas, Seema; Coudhary, Renuka; Aggarwal, Diwakar; Kumar, Manoj; Sharma, Ujjawal; Chaturvedi Parashar, Nidarshana; Haque, Shafiul; Sak, Katrin
    Despite the immense therapeutic advances in the field of health sciences, cancer is still to be found among the global leading causes of morbidity and mortality. Ethnomedicinally, natural bioactive compounds isolated from various plant sources have been used for the treatment of several cancer types and have gained notable attention. Ferulic acid, a natural compound derived from various seeds, nuts, leaves, and fruits, exhibits a variety of pharmacological effects in cancer, including its proapoptotic, cell-cycle-arresting, anti-metastatic, and anti-inflammatory activities. This review study presents a thorough overview of the molecular targets and cellular signaling pathways modulated by ferulic acid in diverse malignancies, showing high potential for this phenolic acid to be developed as a candidate agent for novel anticancer therapeutics. In addition, current investigations to develop promising synergistic formulations are also discussed. � 2022 by the authors.